123 related articles for article (PubMed ID: 36926936)
21. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Khan N; Abbas AM; Koleva YN; Bazzano LA
Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
[TBL] [Abstract][Full Text] [Related]
22. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
[TBL] [Abstract][Full Text] [Related]
23. Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine.
Perrot S; Aslangul E; Szwebel T; Gadhoum H; Romnicianu S; Le Jeunne C
Int J Colorectal Dis; 2007 Sep; 22(9):1119-21. PubMed ID: 17440739
[TBL] [Abstract][Full Text] [Related]
24. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine.
Haralambou G; Teirstein AS; Gil J; Present DH
Mt Sinai J Med; 2001 Nov; 68(6):384-8. PubMed ID: 11687866
[TBL] [Abstract][Full Text] [Related]
25. Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
Ham M; Moss AC
Expert Rev Clin Pharmacol; 2012 Mar; 5(2):113-23. PubMed ID: 22390554
[TBL] [Abstract][Full Text] [Related]
26. Pattern of Inflammation on Surveillance Colonoscopy Does Not Predict Development of Colitis-associated Neoplasia.
Jegadeesan R; Navaneethan U; Gutierrez NG; Venkatesh PG; Hammel JP; Sanaka MR; Shen B
Inflamm Bowel Dis; 2016 Sep; 22(9):2221-8. PubMed ID: 27542134
[TBL] [Abstract][Full Text] [Related]
27. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
28. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
[TBL] [Abstract][Full Text] [Related]
29. Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report.
Suzuki T; Iwamoto K; Nozaki R; Saiki Y; Tanaka M; Fukunaga M; Yamada K
BMC Surg; 2021 Jan; 21(1):50. PubMed ID: 33478454
[TBL] [Abstract][Full Text] [Related]
30. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
[TBL] [Abstract][Full Text] [Related]
31. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
Ullman T; Croog V; Harpaz N; Hossain S; Kornbluth A; Bodian C; Itzkowitz S
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1225-30; quiz 1177. PubMed ID: 18848502
[TBL] [Abstract][Full Text] [Related]
32. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
Bello C; Belaiche J; Louis E; Reenaers C
J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881
[TBL] [Abstract][Full Text] [Related]
33. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P
Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
[TBL] [Abstract][Full Text] [Related]
34. Subtotal colectomy for refractory ulcerative colitis with COVID-19 infection; a first case report in Japan.
Obara N; Koganei K; Tatsumi K; Futatsuki R; Kuroki H; Nakao E; Sugita A
Clin J Gastroenterol; 2021 Oct; 14(5):1437-1442. PubMed ID: 34213760
[TBL] [Abstract][Full Text] [Related]
35. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Zakko SF; Gordon GL; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
Postgrad Med; 2016; 128(3):273-81. PubMed ID: 26861051
[TBL] [Abstract][Full Text] [Related]
36. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
[TBL] [Abstract][Full Text] [Related]
37. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
40. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
